Umbilical cord blood for low platelets after cancer therapy
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether a one-time infusion of umbilical cord blood cells can safely raise platelet counts in people whose counts dropped after cancer treatment. It is for patients whose low platelets are clearly linked to their cancer therapy and who have no other major health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 65 years old.
- Your platelet count is low (below 100,000) because of chemotherapy, targeted therapy, or immunotherapy, and it improved when that treatment stopped.
- You have no other obvious cause for low platelets, like aplastic anemia, leukemia, or an enlarged spleen.
- Your liver and kidney function are mostly normal (within 2.5 times the upper limit).
- You are able to do most of your daily activities (Karnofsky score at least 60 or ECOG 0-2) and your doctor expects you to live more than 3 months.
- You are not allergic to any part of the umbilical cord blood product, and you are not currently in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an injection made from umbilical cord blood to raise low platelet counts caused by cancer therapies like chemo, immunotherapy, or radiation. It may help people with mild to moderate low platelets who haven't had recent platelet transfusions or other platelet-raising drugs.
This trial studies how best to prevent and treat dangerous blood clots in people with cancer who also have very low platelets. It may help guide safer blood-thinner treatment when bleeding risk is high.
This study looks at platelet transfusions—how they’re used and whether platelets function well—for people with blood cancers who have low platelet counts. It may help improve transfusion care for people who need platelet support.
This trial tests a medicine called Romiplostim N01 to help raise platelet levels in people with solid tumors who have low platelets from chemo, radiation, or immunotherapy. The goal is to see if it can safely improve platelet counts so patients can continue their cancer treatment.
This trial tests if a new drug called Romiplostim N01 works better than the standard drug Interleukin-11 for raising low platelet counts caused by cancer treatments like chemotherapy or radiation. If you have low platelets from your cancer therapy, you may be able to join.
This trial tests how well platelet transfusions work for patients with blood cancers or bone marrow failure who have very low platelets and need a transfusion. It aims to see if the transfusions help control bleeding and improve outcomes.
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.